Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects

• Published in: European journal of pharmaceutical sciences Vol. 185; p. 106448
• Main Authors: Jin, Jiangli, Cui, Gang, Mi, Na, Wu, Wei, Zhang, Xin, Xiao, Chunyan, Wang, Jing, Qiu, Xueying, Han, Mai, Li, Ziyan, Wang, Lei, Lu, Tong, Niu, Huikun, Wu, Zhaoxi, Li, Jintong
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2023
• Subjects: Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2 - drug therapy; Dose-Response Relationship, Drug; Double-Blind Method; East Asian People; Fc-fusion protein; Glucagon-Like Peptide 1; Half-Life; Healthy Volunteers; Humans; Oral glucose tolerance test; Pharmacodynamics; Pharmacokinetic; Safety; Type 2 diabetes millitus; Oral glucose tolerance test; Glucagon-like peptide-1; Pharmacodynamics; Type 2 diabetes millitus; Fc-fusion protein; Safety; Pharmacokinetic

TG103 is a novel GLP-1/Fc fusion protein, developed for the treatment of type 2 diabetes and obesity. This trial was designed to assess the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) profiles after single ascending dose of TG103 in healthy Chinese subjects. In this doub...